Genentech, Inc.

Medimmune Limited

F. Hoffmann-la Roche Ag

Medimmue Limited

Binqing Wei

Thomas Pillow

Philip Wilson Howard

John A Flygare

Lewis J Gazzard

Steven T Staben

Timothy Heffron

Steven Huy Do

Michael Siu

Nicole Blaquiere

Stephen Colin Price

Peter Scott Dragovich

Andrew Madin

Bryan K Chan

Mark X Sliwkowski

Rohan V Mendonca

Jun Liang

Brian Salvatore Safina

Alan G Olivero

Robert Andrew Heald

Adrian Folkes

Aleksandr Kolesnikov

Daniel Fred Ortwine

Wendy B Young

Chudi Obioma Ndubaku

James John Crawford

Guiling Zhao

Graham Elgin Jones

Richard A Goldsmith

Sushant Malhotra

Emanuela Gancia

Luke Masterson

Craig Stivala

Danette Dudley

Vishal Verma

Michael Lainchbury

Kin Chiu Fong

Elisia Villemure

Lan Wang

Leanna Staben

Naomi S Rajapaksa

Aihe Zhou

Tim Heffron

Moana Tercel

Joy Drobnick

Yonghan Hu

Janet L Gunzner-Toste

Ho Huat Lee

Aijun Lu

Terry Kellar

Jennafer Dotson

Blake Daniels

Baihua Hu

Jack Sadowsky

Matthew W Cartwright

John Tellis

Anna Giddens

Muriel Bonnet

Guo-Liang Lu

Bohdan Waszkowycz

Andrew Good

David Favor

Robert Anthony Blake

Samantha Alyson Green

Jianfeng Xin

Neville James McLean

Christian Miller

Edna F Choo

Laurent Salphati

Sussie Lerche Krintel

Tracy Kleinheinz

Christian Nilewski

Matthew Leo Landry

Susan Kaufman

Malcolm Huestis

Janet Gunzner-Toste

Neville James Mclean

Naomi Rajapaksa

John C Tellis

Thomas H Pillow

Adrian J Folkes

3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.

Isoquinoline compounds for the treatment of cancer

Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Isoquinoline compounds and uses thereof

Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.

Aza-tetracyclic oxazepine compounds and uses thereof

Naphthyridine compounds and uses thereof

The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.

Tert-butyl (s)-2-(4-(phenyl)-6H-thieno[3, 2-f][1, 2, 4]triazolo[4, 3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain BRD4 inhibitors for treating cancer

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.

Peptidomimetic compounds and antibody-drug conjugates thereof

The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.

(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof

Conjugate compounds of formula (A): wherein: where Rand Rare independently selected from H, F, Csaturated alkyl, Calkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from Calkyl amido and Calkyl ester; or, when one of Rand Ris H, the other is selected from nitrile and a Calkyl ester; 

Pyrrolobenzodiazepines and conjugates thereof

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.

Conjugate compounds of formula (A): wherein:  

Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Benzoxepin PI3K inhibitor compounds and methods of use

Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and where (i) Xis N and Xis S, (ii) Xis S and Xis N, (iii) Xis CRand Xis S, (iv) Xis S and Xis CR; (v) Xis NRand Xis N, (vi) Xis N and Xis NR, (vii) Xis CRand Xis O, (viii) Xis O and Xis CR, (ix) Xis CRand Xis C(R), (x) Xis C(R)and Xis CR; (xi) Xis N and Xis O, or (xii) Xis O and Xis N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Growing community of inventors

South San Francisco, CA, United States of America

Binqing Wei